menu
    • menu
    [{"orgOrder":0,"company":"CR Double-Crane Pharmaceuticals Co., Ltd","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CR Double-Crane Pharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CR Double-Crane Pharmaceuticals Co., Ltd \/ CR Double-Crane Pharmaceuticals Co., Ltd","highestDevelopmentStatusID":"4","companyTruncated":"CR Double-Crane Pharmaceuticals Co., Ltd \/ CR Double-Crane Pharmaceuticals Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by CR Double-Crane Pharmaceuticals Co., Ltd

    Menu

    CR Double-Crane Pharmaceuticals Co., Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CR Double-Crane Pharmaceuticals Co., Ltd

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CR Double-Crane Pharmaceuticals Co., Ltd

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Ligand Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligandâ...

                            Details : Ligand has preclinical data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous co...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 21, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Ligand Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth